Site Editor
Leo I. Gordon, MD, FACP
Leo I. Gordon, MD, FACP
Posted: Monday, February 6, 2023
According to Catherine S. Diefenbach, MD, of the Perlmutter Cancer Center, NYU Langone Health, New York, and colleagues, there is an unmet medical need for patients with relapsed or refractory follicular lymphoma. Consequently, these investigators evaluated the safety and efficacy of the antibody-drug conjugate polatuzumab vedotin-piiq plus obinutuzumab and lenalidomide in this population. The final analysis of this novel triplet combination was presented during the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition (Abstract 951).
“High complete response rates at [the] end of induction in a heavily pretreated and refractory population compare favorably with currently available relapsed or refractory follicular lymphoma therapies,” concluded the study authors. “More than half of the patients treated with [this therapy combination] had not experienced disease progression after 4 years.”
This phase Ib/II, open-label study enrolled 56 patients with relapsed or refractory follicular lymphoma who had received at least one prior anti-CD20–containing chemoimmunotherapy regimen. Participants in the expansion cohort underwent induction treatment with six 28-day cycles of intravenous polatuzumab vedotin and obinutuzumab, as well as oral lenalidomide. Responders received maintenance treatment for 24 months.
At the median follow-up of 43.3 months, the primary efficacy population (n = 46) demonstrated an objective response rate of 76% and a complete response rate of 61%. The best overall response rate by investigator assessment was 91%, and the best complete response rate was 72%. Although the progression-free survival rates at 12, 24, and 48 months were 83%, 67%, and 53%, respectively, median progression-free survival and overall survival were not reached.
At the median follow-up of 43.5 months, all patients experienced at least one adverse event; serious and grade 3 or 4 adverse events affected 64% and 48% of participants, respectively. The most common grade 3 or 4 adverse events were neutropenia, infections, thrombocytopenia, and anemia. Dose interruptions, reductions, and treatment discontinuation because of adverse events were reported in 43%, 32%, and 34% of individuals, respectively.
Disclosure: For full disclosures of the study authors, visit ash.confex.com.
2022 ASH Annual Meeting and Exposition
